Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes | Macquarie University ResearchOnline

Home

Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes

Please use this identifier to cite or link to this item: http://hdl.handle.net/1959.14/112830

48 Visitors

51 Hits

0 Downloads

Title: Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes
Related: Journal of cardiology, Vol. 55, No. 3 (2010), p.303-308
DOI: 10.1016/j.jjcc.2009.12.002
Publisher: Elsevier
Date: 2010
FoR/RFCD Code(s): 110201 Cardiology (incl. Cardiovascular Diseases) 010402 Biostatistics
Author/Creator: Ge, JunBo
Author/Creator: Kim, Young-Jo
Author/Creator: Jang, Yang-Soo
Author/Creator: Zhu, JunRen
Author/Creator: Marschner, Ian C
Author/Creator: Lam, William
Description: Background Studies in Western populations have shown the benefits of pretreatment with atorvastatin in preventing cardiovascular events in patients, including those with acute coronary syndromes (ACS), undergoing percutaneous coronary intervention (PCI). However, data concerning the value of such therapy in Asian patients are limited. The primary objective of the present study is to evaluate the efficacy of atorvastatin in reducing cardiovascular outcomes in Asian patients with non-ST-segment elevation (NSTE)-ACS following hospital admission for early PCI (within 72 h of the onset of symptoms). Secondary objectives are to assess the effects of atorvastatin on cardiac biomarker levels, and the safety and tolerability profile of atorvastatin. Methods This study is a prospective, multicenter, open-label trial designed to enroll 350 statin-naïve patients with NSTE-ACS scheduled for PCI in China and the Republic of Korea. Patients are randomized to either usual care or atorvastatin treatment groups, with patients in both treatment groups receiving usual care including atorvastatin 40 mg/day for 30 days post-PCI. Patients in the atorvastatin group receive additional doses of atorvastatin 80 mg at 12 h pre-PCI and 40 mg at 2 h pre-PCI. The primary end point is the incidence of major adverse cardiac events (death, myocardial infarction, and target vessel revascularization) at 30 days post-PCI. Conclusions The present study will provide valuable insights into whether the benefits of atorvastatin pretreatment extend to Asian patients with ACS undergoing interventions. Enhanced treatment of these patients will be an important contribution towards alleviating the increasing burden of cardiovascular disease in Asian countries.
Description: 6 page(s)
Subject Keyword: 110201 Cardiology (incl. Cardiovascular Diseases)
Subject Keyword: 010402 Biostatistics
Subject Keyword: angiography
Subject Keyword: cholesterol-lowering drugs
Subject Keyword: coronary artery disease
Subject Keyword: prevention
Resource Type: journal article
Organisation: Macquarie University. Dept. of Statistics

Identifier: http://hdl.handle.net/1959.14/112830
Identifier: ISSN:0914-5087
Identifier: mq-rm-2010001802
Language: eng
Reviewed

Macquarie University ResearchOnline

Search

Browse

Highlights

Resources